Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma | NEJM
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma - ScienceDirect
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial - The Lancet Oncology
Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience | Anticancer Research
FIG URE 1 Unadjusted (A) and adjusted (B) overall survival in... | Download Scientific Diagram
Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real‐life outcomes of daratumumab treatment - Afram - 2020 - European Journal of Haematology - Wiley Online Library
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials - The Lancet Haematology
MAIA results confirm superior efficacy of daratumumab with standard-of-care - Medical Conferences
Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens: Efficacy in transplant‐ineligible untreated myeloma - Durie - 2020 - American Journal of Hematology - Wiley Online Library
EHA Library - The official digital education library of European Hematology Association (EHA)
Daratumumab, Lenalinomide, and Dexamethasone for Myeloma | NEJM Resident 360
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study | Leukemia
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma | NEJM
Cancers | Free Full-Text | Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
MAIA Study | Int'l Myeloma Foundation
Overall Survival Benefit Reported With Daratumumab Plus Lenalidomide in Myeloma - The ASCO Post
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA | Leukemia
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial | Journal of Clinical Oncology
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR | Haematologica
Upfront Daratumumab Shows Survival Benefit in Combination for Transplant-Ineligible Multiple Myeloma - Cancer Therapy Advisor
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet
A. Overall survival after daratumumab treatment. B. Overall survival by... | Download Scientific Diagram
Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
